You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. An Epithermal Neutron Source for Cancer Therapy

    SBC: ADELPHI TECHNOLOGY INC            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to develop a commercial neutron source for the treatment of brain and liver cancer based on boron neutron capture therapy (BNCT). Boron-containing compounds are injected into a patient's bloodstream and accumulate in a malignant tumor. When irradiated with neutrons, the boron atoms preferentially capture neutrons and decay, releasing short-range radi ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Directed Differentiation of Embryonic Stem Cells using Phage Displayed Ligands

    SBC: OCATA THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The ability to culture human embryonic stem cells generated a great deal of excitement about their vast potential for treating a variety of human diseases such as diabetes, heart disease, neurological, retinal and skin disorders to name a few. Unlike adult stem cells, embryonic stem cells have indefinite growth potential and the potential to develop into any t ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Auto-antibody profiling of non-small cell lung cancer

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Tumor markers, measured in peripheral blood, could assist in diagnosis and management of non-small cell lung cancer (NSCLC) and potentially improve historically dismal outcomes. Circulating antibodies, generated to a wide range of tumor-associated proteins, can be translated into a valuable blood test for lung cancer. Preliminary data supports this hypothesis. ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Study of CdZnTe Electrode Interface and Fabrication Technology Development

    SBC: Aguila Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): In several recent PA's, the NIH has articulated a clear vision for the future of medical imaging systems a) enhanced spatial or temporal resolution, b) better sensitivity and specificity, c) multi-modality, and d) new functional or molecular imaging or spectroscopy methods. Owing to their unique combination of properties, direct conversion gamma radiation imagi ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Oral Formulation of Zonulin Antagonist AT-1001 for Diabe

    SBC: ALBA THERAPEUTICS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The trigger for autoimmune destruction of pancreatic beta cells in Type 1 diabetes (T1D) is unclear. Evidence exists for the role of increased intestinal permeability, secondary to intestinal tight junctions (tj) disassembly, in the pathogenesis of various autoimmune diseases including T1 D. Over the last decade our studies have focused on the mechanism(s) of a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. High-Energy Imaging in Support of Radionuclide Therapy

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to design and build cameras that can efficiently detect and image isotopes that have gamma rays with energies that are typically beyond those effectively accessible with conventional cameras. There are no nuclear medicine clinical cameras, today, that combine high efficiency with the ability to image high-energy gamma rays. ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. New APEX diagnostic for hereditary sensorineural hearing loss

    SBC: APEX DX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): In developed countries, approximately 1:1000 children are born deaf and approximately 1:300 children are born with some lesser degree of hearing loss. At least 50% of the deafness and hearing impairment is likely to be attributable to genetic factors, with a large number of genes involved in the pathogenesis. The molecular genetic basis for the majority of case ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Safety of intraarticular N-acetylglucosamine

    SBC: ARTYX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Mobile Training of Skilled Support Personnel

    SBC: BANDEMAR NETWORKS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant) Skilled Service Personnel (SSP) support emergency response organizations during an emergency incident involving weapons of mass destruction and include laborers, operating engineers, carpenters, ironworkers, sanitation workers and utility workers. SSP called to an emergency incident rarely have recent detailed training on the chemical, biological, radiological, ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. New Opioids for Alcoholism

    SBC: BEHAVIORAL PHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Highly potent, orally active, metabolically stable, long-lived opioid agents for the treatment of alcoholism that have decreased side effects such as nausea, addiction liability, immunosuppression and respiratory depression represents a great unmet need. While a mu opioid receptor antagonist is currently approved by the FDA for alcoholism, it possesses several ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government